REALQUALITY RQ-HHV 8
REALQUALITY RQ-HHV 8 is a diagnostic CE-IVD kit for the identification and quantification of the DNA of Human Herpes virus type 8 (HHV 8) by Real time PCR
The device is validated on DNA extracted from various samples types
The assay requires only 5 µL of DNA extracted
If used in combination with the REALQUALITY RQ-HHV 8 STANDARD, it allows the quantification of the viral DNA present in the sample
The assay shares the same thermal profile of the REALQUALITY Infectious diseases kits
Validated on main Real time PCR instruments
The assay includes dUTP/UNG system for preventing carry-over contamination and a fluorescence normalizer
The automatic format of the assay can be used on GENEQUALITY X120 platform
Easy interpretation of results with AB Genius Report software
Ready-to-use reagents for Real time PCR
Internal control (amplification of beta-globin gene - BG)
Positive control (DNA containing fragments of the HHV 8 genome and the BG gene)
For further information
Human Herpes virus 8 (HHV 8) is a herpetic virus that was first isolated in 1994.
As with the other herpetic viruses, after an initial infection accompanied by fever and the appearance of a rash, HHV 8 enters a latency phase. However, it is not a ubiquitous virus and the seroprevalence of HHV 8 in the human population is not uniform. Its geographical distribution is heterogeneous; the greatest seroprevalence of the virus undoubtedly occurs in sub-Saharan Africa, followed by South America, Asia and the Mediterranean basin countries. Transmission of the virus occurs through salivary secretions, sexual activity, transfusions or transplant of an infected organ.
Reactivation of the virus in immunosuppressed patients may lead to the onset of Kaposi's sarcoma, a form of multicentric vascular tumour. As well as individuals with AIDS, transplant patients also have a high risk of developing Kaposi’s sarcoma, which occurs 22-24 months after the transplant on average.
Why use Real time PCR assay for HHV 8?
The search for HHV 8 using Real time PCR is essential to the timely identification of viral reactivation in organ transplant recipients and their subsequent follow-up.
This product uses technology patented by Biosearch Technologies, licensed for use in Human Molecular Diagnostic applications.